{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:20:39Z","timestamp":1790115639208,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.pnpbp.2011.03.011","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T05:14:23Z","timestamp":1301980463000},"page":"1112-1116","source":"Crossref","is-referenced-by-count":12,"title":["Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia"],"prefix":"10.1016","volume":"35","author":[{"given":"Alessandro","family":"De Risio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Pancheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Stefanutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2011.03.011_bb0005","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00002018-200629070-00004","article-title":"Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?","volume":"29","author":"Aichhorn","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157488610789869265","article-title":"QT alterations in psychopharmacology: proven candidates and suspects","volume":"5","author":"Alvarez","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/schbul\/sbn030","article-title":"Does the addition of a second antipsychotic drug improve clozapine treatment?","volume":"35","author":"Barbui","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0025","series-title":"The professionals' pocket handbook & aide memoire","article-title":"Psychotropic drug directory, 2005","author":"Bazire","year":"2005"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1745017901006010030","article-title":"Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study","volume":"6","author":"Benedetti","year":"2010","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0035","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/schbul\/21.4.579","article-title":"Clozapine: efficacy and safety","volume":"21","author":"Buchanan","year":"1995","journal-title":"Schizophr Bull"},{"issue":"4","key":"10.1016\/j.pnpbp.2011.03.011_bb0040","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.v69n0505","article-title":"Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double blind, placebo-controlled trial","volume":"69","author":"Chang","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. II","key":"10.1016\/j.pnpbp.2011.03.011_bb0050","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1590\/S1516-44462007000600002","article-title":"Refractory schizophrenia","volume":"29","author":"Elkis","year":"2007","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0055","first-page":"1","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"12","author":"Fleischhacker","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000098491","article-title":"Discriminant ability and criterion validity of the HoNOS in Italian psychiatric residential facilities","volume":"40","author":"Gigantesco","year":"2007","journal-title":"Psychopathology"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0091-3057(94)90243-7","article-title":"Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain","volume":"49","author":"Inoue","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0075","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/YCO.0b013e328314e144","article-title":"The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia","volume":"21","author":"Juckel","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0085","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.pnpbp.2008.02.010","article-title":"Combined antipsychotic treatment involving clozapine and aripiprazole","volume":"32","author":"Englisch","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0269881106068289","article-title":"Is clozapine\u2013aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?","volume":"21","author":"Karunakaran","year":"2007","journal-title":"J Psychopharm"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0095","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0100","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/11310820-000000000-00000","article-title":"Aripiprazole: dose\u2013response relationship in schizophrenia and schizoaffective disorders","volume":"23","author":"Mace","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hup.915","article-title":"Cardiac side effects of psychiatric drugs","volume":"23","author":"Mackin","year":"2008","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pnpbp.2006.09.015","article-title":"Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study","volume":"31","author":"Mitsonis","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0120","first-page":"310","article-title":"Real life experiences: a doctor's account","volume":"15","author":"Moretti","year":"2009","journal-title":"Giorn Ital Psicopat"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0230","unstructured":"Morosini PL, Casacchia M. Traduzione italiana della Brief Psychiatric Rating Scale, versione 4.0 ampliata (BPRS 4.0). Rivista di Riabilitazione Psichiatica e Psicosociale 1995;3:199\u2013228."},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1017\/S1121189X00006059","article-title":"HoNOS-Rome: an extended, customized, and longitudinal oriented version of the HoNOS","volume":"12","author":"Morosini","year":"2003","journal-title":"Epidemiol Psichiatr Soc"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0135","series-title":"XVII National Congress of Societ\u00e0 Italiana di Neuropsicofarmacologia, Cagliari, 22th\u201325th September, 2010, Abstract Book","first-page":"96","article-title":"Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind placebo-controlled study","author":"Muscatello","year":"2010"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","article-title":"Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia","volume":"30","author":"Nasrallah","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1745-6215-10-31","article-title":"Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia","volume":"10","author":"Nos\u00e8","year":"2009","journal-title":"Trials"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0150","series-title":"Riconoscimento e gestione","first-page":"168","article-title":"Le emergenze psichiatriche in medicina","author":"Pallanti","year":"2007"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0155","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0b013e318036bfbb","article-title":"Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis","volume":"27","author":"Paton","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0160","first-page":"315","article-title":"A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects","volume":"31","author":"Pollack","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0165","first-page":"63","article-title":"Use of quetiapine to manage patients who experience adverse effects with clozapine: a meta-analysis","volume":"23","author":"Reinstein","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0170","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0447.1999.tb10850.x","article-title":"Reliability of an Italian standardized and expanded Brief Psychiatric Rating Scale (BPRS 4.0) in raters with high vs. low clinical experience","volume":"100","author":"Roncone","year":"1999","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000067062","article-title":"Is theory of mind in schizophrenia more strongly associated with clinical and social functioning than with neurocognitive deficits?","volume":"35","author":"Roncone","year":"2002","journal-title":"Psychopathology"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0180","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2174\/138920010791636202","article-title":"Atypical antipsychotic metabolism and excretion","volume":"11","author":"Sheehan","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0185","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1192\/bjp.171.6.569","article-title":"Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study","volume":"171","author":"Shiloh","year":"1997","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2011.03.011_bb0195","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.clinthera.2010.01.021","article-title":"Aripiprazole in schizophrenia and schizoaffective disorder: a review","volume":"32","author":"Stip","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0200","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug\u2013drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0205","first-page":"221","article-title":"Training and quality assurance with the Brief Psychiatric Rating Scale: \u201cthe drift busters\u201d","volume":"3","author":"Ventura","year":"1993","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0210","first-page":"227","article-title":"Manual for the Expanded Brief Psychiatric Rating Scale","volume":"3","author":"Ventura","year":"1993","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.172.1.11","article-title":"Health of the Nation Outcome Scales (HoNOS). Research and development","volume":"172","author":"Wing","year":"1998","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00044011-200626030-00001","article-title":"Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: an open clinical study","volume":"26","author":"Ziegenbein","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pnpbp.2011.03.011_bb0225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","article-title":"Polypharmacy in schizophrenia","volume":"23","author":"Zink","year":"2010","journal-title":"Curr Opin Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:06:53Z","timestamp":1741122413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584611000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0278584611000960"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.03.011","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}